N4-({4-[(dimethylamino)methyl]cyclohexyl}methyl)-N2-(1-naphthylmethyl)-5-nitropyrimidine-2,4-diamine | 736047-57-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N4-({4-[(dimethylamino)methyl]cyclohexyl}methyl)-N2-(1-naphthylmethyl)-5-nitropyrimidine-2,4-diamine
• 英文别名: N4-({4-cis-[(dimethylamino)methyl]cyclohexyl}methyl)-N2-(1-naphthylmethyl)-5-nitropyrimidine-2,4-diamine；4-N-[[4-[(dimethylamino)methyl]cyclohexyl]methyl]-2-N-(naphthalen-1-ylmethyl)-5-nitropyrimidine-2,4-diamine
• CAS: 736047-57-7
• 化学式: C₂₅H₃₂N₆O₂
• 分子量: 448.568
• InChiKey: QAFMHIPCIOLDLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  98.9
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Stem cell modulation II
  申请人：University of Canberra

  公开号：US10736892B2

  公开（公告）日：2020-08-11

  Disclosed are methods and compositions for modulating cancer stem cells. More particularly, the present invention discloses the use of protein kinase C theta inhibitors (PKC-θ) for inhibiting the growth of PKC-θ-overexpressing cells including cancer stem cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells, for treating cancer, including metastatic cancer and/or for preventing cancer recurrence.

  本发明公开了调节癌症干细胞的方法和组合物。更具体地说，本发明公开了蛋白激酶C theta抑制剂（PKC-θ）的用途，用于抑制包括癌症干细胞在内的PKC-θ过表达细胞的生长，增强化疗药物或照射对癌细胞的生物效应，治疗癌症，包括转移性癌症和/或预防癌症复发。
• STEM CELL MODULATION II
  申请人：University of Canberra

  公开号：EP3046560A1

  公开（公告）日：2016-07-27
• COMPOSITIONS FOR MODULATING CANCER STEM CELLS AND USES THEREFOR
  申请人：University of Canberra

  公开号：EP3185858A1

  公开（公告）日：2017-07-05
• IMMUNOGENIC COMPOSITIONS AND USES THEREFOR
  申请人：Epiaxis Therapeutics Pty Ltd

  公开号：EP3706776A1

  公开（公告）日：2020-09-16
• Stem Cell Modulation II
  申请人：University of Canberra

  公开号：US20190192509A1

  公开（公告）日：2019-06-27

  Disclosed are methods and compositions for modulating cancer stem cells. More particularly, the present invention discloses the use of protein kinase C theta inhibitors (PKC-θ) for inhibiting the growth of PKC-θ-overexpressing cells including cancer stem cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells, for treating cancer, including metastatic cancer and/or for preventing cancer recurrence.